Form 4: Twist Bioscience CFO Adam Laponis Acquires 20,000 Shares of Common Stock

Adam Laponis, CFO of Twist Bioscience, reports the acquisition of 20,000 shares of common stock on November 4, 2024, as a result of performance stock units meeting their target criteria.

Summary

• On November 4, 2024, Adam Laponis, the Chief Financial Officer of Twist Bioscience Corp, acquired 20,000 shares of common stock.
• The acquisition was related to performance stock units (PSUs) for which the target criteria were met.
• 60% of these PSUs are subject to time-based vesting and will vest on October 1, 2025, contingent upon continued service.
• Following the transaction, Laponis directly owns 93,397 shares of Twist Bioscience common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard executive compensation event (PSU vesting) tied to performance.

Positives

• The vesting of performance stock units suggests that the company has achieved certain performance targets, which could be viewed positively.

Future Outlook

60% of the PSUs will vest on October 1, 2025, subject to continued service or acceleration of vesting as provided in the award agreement.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in beneficial ownership by a company's officer.

Stakeholder Impact

• The vesting of PSUs aligns management's interests with those of shareholders, potentially driving long-term value creation.

Key Dates